MARATTO

article · Labyrinth : Fayoum University Journal Of Science and Interdisciplinary Studies

Study of prevelance of Metabolic associated Fatty Liver Disease (MAFLD) in Fayoum Governorate

2024Open accessBeni Suef University

Abstract

Background and aim; the liver affection in metabolic syndrome is called metabolic associated fatty liver diseases (MAFLD)which is associated with insulin resistance, obesity, diabetes mellitus (DM) type 2. This study aimed to identify prevalence of metabolically associated fatty liver disease (MAFLD) in Fayoum. Patients and methods; our cross sectional study was conducted on 1061 persons of simple random samples in Fayoum University Hospital. They were clinically assessed and investigated by laboratory tests including Liver enzymes, serum lipid profile, imaging i.e., abdominal ultrasound, transient elastography (fibroscan). Results; about two thirds of study participants 715/1061 (67.4%) were classified to have MAFLD. patients with MAFLD were older than those without MAFLD, near one third of study participants319/1061 (30.1%) had normal weight, less than half 456/1061 (43.1%) were overweight, while 285/1061 (26.9%) were obese. Less than half of the study participants; 464/1061 (43.7%) and 492/1061 (46.4%) were diabetics and hypertensive. Conclusion; our findings showed that the prevalence of MAFLD in the study population was high. Higher body mass index (BMI), waist circumference, triglyceride, LDL, fasting plasma glucose, were risk factors for MAFLD. Patients with MAFLD were older than those without MAFLD. Prevalence rate of MAFLD was found to be higher in females than males.

Research topics

  • Liver Disease Diagnosis and Treatment

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ifjsis.2024.263057.1054

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.